> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# X4 Pharmaceuticals Refinances Hercules Debt With $80 Million K2 Loan Due In 2030
- URL: https://www.bullished.co/x4-pharmaceuticals-refinances-hercules-debt-with-80-million-k2-loan-due-in-2030-77698e84/
- Published: 2026-11-04T22:33:30.000Z
- Updated: 2026-11-04T22:33:30.000Z
- Description: The new facility pushes out a July 2027 maturity, adds a market-value cash covenant from 2027, and lets lenders convert up to $15.0 million into stock.
- Author: Matteo Parrino
- Tags: SEC Filings, XFOR, Industry: Healthcare

[X4 Pharmaceuticals](https://www.bullished.co/tag/xfor/), which develops and sells treatments for rare blood diseases, retired its Hercules loan on October 7 with an [$80.0 million first-tranche loan](https://www.sec.gov/Archives/edgar/data/0001501697/000150169726000089/xfor-20260930.htm?ref=bullished.co) from K2 HealthVentures, the company said in its quarterly report filed Wednesday. The new debt matures in October 2030, and its lenders can swap up to $15.0 million of principal into stock.

## Terms of the K2 loan

The K2 agreement allows term loans of up to $150.0 million. The $80.0 million first tranche arrived October 7; the remaining $70.0 million depends on X4 requesting it and the lenders choosing to approve it.

X4 used substantially all of the proceeds to repay Hercules in full: $75.0 million of principal, $2.8 million of end-of-term fees and $0.8 million of early termination and other fees. The company put the total payoff at about $78.7 million.

Cash interest is the greater of 8.55% or the prime rate plus 1.55%, with an extra 1.0% a year paid in kind. Payments are interest-only through October 1, 2029, followed by principal and interest for 13 months. The interest-only period extends to maturity if X4 achieves first U.S. commercial sales of mavorixafor in chronic neutropenia, among other conditions.

The lenders may convert up to $15.0 million of principal into common stock at $3.2341 per share, subject to certain beneficial ownership limits. The debt is secured by substantially all assets other than intellectual property.

## Covenants tied to market value

Starting October 1, 2027, whenever X4's market capitalization is below $800.0 million, it must hold unrestricted cash of at least 75% of its K2 obligations. That threshold falls to 40% once certain conditions are met. Market capitalization stood at $314 million in Wednesday's report-day data, with the stock at $3.24.

A second test starts April 1, 2029: product sales over any three months must equal at least 50% of what the board-approved projections call for.

The Hercules balance of $77.0 million had been due July 1, 2027, [per the prior quarterly report](https://www.sec.gov/Archives/edgar/data/0001501697/000150169726000068/xfor-20260630.htm?ref=bullished.co). Because X4 showed the intent and ability to refinance before issuing its statements, the balance is classified as long-term debt rather than a current liability.

## Cash, losses and the 4WARD trial

X4 held $187.7 million of cash, cash equivalents and short-term securities at September 30\. It lost $56.6 million over the first nine months of 2026 and used $60.6 million in operations, and says that cash should fund operations and debt for at least 12 months.

Product sales of Xolremdi were $2.8 million in the third quarter against $1.6 million a year earlier. Total operating expenses fell to $22.9 million from $29.3 million.

In its pivotal 4WARD trial in chronic neutropenia, the FDA said in August that cutting enrollment from 176 to 126 participants keeps adequate power for the co-primary endpoints. X4 expects to finish enrolling by the end of 2026.

X4 expects to complete 4WARD enrollment by the end of 2026, and the market-value cash covenant begins October 1, 2027.

### Sources

- [10-Q Filing — X4 Pharmaceuticals (XFOR)](https://www.sec.gov/Archives/edgar/data/0001501697/000150169726000089/xfor-20260930.htm?ref=bullished.co) — SEC EDGAR
- [10-Q Filing — X4 Pharmaceuticals (XFOR), Q2 FY2026 filed 2026-08-06 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0001501697/000150169726000068/xfor-20260630.htm?ref=bullished.co) — SEC EDGAR
- [8-K Filing — X4 Pharmaceuticals, filed 2026-10-29 (Items 8.01, 9.01)](https://www.sec.gov/Archives/edgar/data/0001501697/000150169726000084/xfor-20261029.htm?ref=bullished.co) — SEC EDGAR
- [X4 Pharmaceuticals: Q3 Earnings Snapshot | 11alive.com](https://www.11alive.com/article/syndication/associatedpress/x4-pharmaceuticals-q3-earnings-snapshot/616-51dd7d9c-c0e6-466a-9171-af63cdb59818?ref=bullished.co) — Associated Press
- [X4 Pharmaceuticals Reports Third Quarter 2026 Financial](https://www.globenewswire.com/news-release/2026/11/04/3395871/0/en/x4-pharmaceuticals-reports-third-quarter-2026-financial-results-and-provides-corporate-update.html?ref=bullished.co) — globenewswire.com
- [X4 Pharmaceuticals to Participate in Guggenheim, Stifel,](https://www.globenewswire.com/news-release/2026/11/03/3394839/0/en/x4-pharmaceuticals-to-participate-in-guggenheim-stifel-and-jefferies-conferences-in-november-2026.html?ref=bullished.co) — globenewswire.com

### More on X4 Pharmaceuticals

- [X4 Pharmaceuticals Plans A 25-Patient Trial To Cut Neutropenia Patients' G-CSF Doses, Starting In First Quarter Of 2027](https://www.bullished.co/x4-pharmaceuticals-plans-a-25-patient-trial-to-cut-neutropenia-patients-g-csf-doses-75305864/)
- [X4 Pharmaceuticals Takes Up To $150 Million K2 Loan, Pays Off $75 Million Hercules Principal](https://www.bullished.co/x4-pharmaceuticals-takes-up-to-150-million-k2-loan-pays-off-75-million-hercules-principal-e9fc2e29/)

[All X4 Pharmaceuticals (XFOR) coverage →](https://www.bullished.co/tag/xfor/)